ABSI
HealthcareAbsci Corporation · Biotechnology · $800M
What is Absci Corporation?
Absci Corporation is a small-cap drug and target discovery company headquartered in Vancouver, Washington, focused on accelerating biologic drug creation through an integrated technology platform.
Absci's integrated drug creation platform unifies drug discovery and cell line development into a single process, enabling partners to generate biologic drug candidates and production cell lines more efficiently. The company primarily serves pharmaceutical and biotech partners in the United States, generating revenue through collaborations and licensing arrangements.
Absci was founded in 2011 and is headquartered in Vancouver, Washington.
- Integrated drug creation platform
- Biologic drug candidate generation
- Production cell line development
- Partner collaboration and licensing
Is ABSI a Good Stock to Buy?
UQS Score rates ABSI as Poor overall, reflecting meaningful challenges across several key quality dimensions.
The Risk pillar stands out as a relative bright spot, suggesting the company maintains a manageable balance sheet profile compared to some peers at a similar stage.
Both the Quality and Moat pillars are rated Weak, and Valuation is Elevated — a combination that warrants careful scrutiny for investors evaluating this name.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ABSI pay dividends?
No — Absci Corporation does not currently pay a dividend.
Absci does not currently pay a dividend. As an early-stage drug discovery company, capital is directed toward platform development, research, and partnership growth rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does ABSI report earnings?
Absci Corporation reports earnings on a quarterly cadence, typical for US-listed equities.
As a pre-profitability biotech, Absci's quarterly results are closely watched for partnership milestones and platform progress rather than traditional earnings metrics. Revenue visibility remains limited given the collaboration-driven business model.
For the most recent quarter's results, visit Absci Corporation's investor relations page directly.
ABSI Price History
-86.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Absci Corporation?
Based on Absci Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Absci Corporation do?
Absci Corporation develops an integrated drug creation platform that combines drug discovery and cell line development into one unified process. The company partners with pharmaceutical and biotech firms to generate biologic drug candidates and production cell lines, primarily serving the US market.
Does ABSI pay dividends?
No, ABSI does not pay a dividend. Absci is an early-stage company that reinvests available capital into its platform and research operations. Investors seeking dividend income should look elsewhere.
When does ABSI report earnings?
Absci reports on a standard quarterly schedule. For exact upcoming dates, check the company's investor relations page, as our data source does not cover specific future earnings dates.
Is ABSI a good stock to buy?
UQS Score rates ABSI as Poor, driven by Weak Quality and Moat scores alongside an Elevated Valuation. The Risk pillar is a relative positive. Investors should weigh these factors carefully against their own risk tolerance and time horizon.
Is ABSI overvalued?
The UQS Valuation pillar for ABSI is rated Elevated, suggesting the current market price may not be well-supported by the company's underlying fundamentals at this stage. Pro members can view the full valuation metrics behind this rating.
What is ABSI's market cap bracket?
Absci Corporation is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers in the healthcare sector.
Is ABSI a long-term quality investment?
From a long-term quality perspective, ABSI's current UQS profile — with Weak Quality and Moat pillars — indicates the company has not yet established the durable fundamentals typically associated with high-quality long-term holdings. Platform maturation and partnership traction will be key to watch.
What sector does ABSI belong to?
Absci Corporation operates in the Healthcare sector, specifically within drug and target discovery. The company sits at the intersection of biotechnology and computational drug design, serving larger pharma and biotech partners through its platform.
Unlock Full ABSI Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete pillar-by-pillar score breakdown for ABSI
- ✓Access detailed financial metrics behind each UQS rating
- ✓Compare ABSI against sector peers on quality and valuation
- ✓Get the full analyst-style quality report for Pro members
Pro Analysis
ABSI — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | 24.5 | 0.0 | 18.0 | 43.7 | 74.9 | 0.0 | +0.1 |
| Apr 2, 2026 | 24.4 | 0.0 | 18.0 | 43.7 | 74.1 | 0.0 | — |
ABSI — Pillar Breakdown
Quality
— 0.0/100 (25%)Absci Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 43.7/100 (20%)Absci Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.9/100 (15%)Absci Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Absci Corporation appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 18/100 (25%)Absci Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ABSI.
Score Composition
Financial Data
More Stock Analysis
How is the ABSI UQS Score Calculated?
The UQS (Unified Quality Score) for Absci Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Absci Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Absci Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.